A Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 90.9, 181.8 and 363.6 microg b.i.d. Administered Via Respimat (R) Inhaler and Fluticasone Propionate HFA MDI 440 microg b.i.d. in Patients With Asthma Inadequately Controlled on Medium Dose ICS Therapy.

Trial Profile

A Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 90.9, 181.8 and 363.6 microg b.i.d. Administered Via Respimat (R) Inhaler and Fluticasone Propionate HFA MDI 440 microg b.i.d. in Patients With Asthma Inadequately Controlled on Medium Dose ICS Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs BI 54903 (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 26 Jul 2012 Actual patient number changed from 8 to 9 as reported by ClinicalTrials.gov record.
    • 17 Mar 2012 Planned end date changed from 1 Mar 2013 to 14 Feb 2014 as reported by European Clinical Trials Database record.
    • 16 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top